Characterization of withanolides and bacoside A-loaded proniosomes : effect on oxidative stress and survival under hypergravity in rodent model
OBJECTIVE: This work provides characterization of withanolides and bacoside A proniosomes, and evaluating their potency in rat model for combating oxidative stress-induced blood-brain barrier (BBB) damage and their survival under hypergravity.
SIGNIFICANCE: The delivery system was aimed for sustained drug release in plasma and brain, which could improve their efficiency and provide a therapeutic approach to combat oxidative damage and restore BBB integrity.
METHODS: Proniosomes were prepared using withanolides extracted from the roots of W. somnifera and bacoside A derived from the leaf extract of B. monnieri by thin film hydration technique. In vitro release of withanolides and bacoside A from the proniosomes was studied. In vivo experiments were conducted in Wistar Albino rat model to evaluate the efficacy of drug-loaded proniosomes in improving the antioxidant activity in plasma and brain, restoring BBB integrity and combating hypergravity conditions.
RESULTS: The withanolides and bacoside A-loaded proniosomes showed slow and sustained release of just 62.0 ± 2.87 and 62.9 ± 3.41%, respectively, in 9 h period against the release of 98-99% for the extracts that served as control. Trials conducted in vivo revealed a significant (p < .05) increase in the activity of antioxidant enzymes in both plasma and brain. Also, minimal extravasation of Evans blue dye into the brain (15 ± 0.03 and 16 ± 0.03 ng/g in treated groups against 110 ± 0.01 ng/g in control) of the rats fed with drug-loaded proniosomes was indicative of minimal damage to BBB. Rats fed with drug-loaded proniosomes survived to the extent of 75-83.3% against simulated hypergravity as compared to the control group in which only 50% survived.
CONCLUSION: Proniosomes provided sustained release of drugs, which helped to protect BBB integrity, thereby combating hypergravity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Drug development and industrial pharmacy - 49(2023), 12 vom: 30. Dez., Seite 748-758 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saunshi, Yallappa B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antioxidants |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 22.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03639045.2023.2286702 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365284424 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365284424 | ||
| 003 | DE-627 | ||
| 005 | 20231227135956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03639045.2023.2286702 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1235.xml |
| 035 | |a (DE-627)NLM365284424 | ||
| 035 | |a (NLM)38037324 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saunshi, Yallappa B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characterization of withanolides and bacoside A-loaded proniosomes |b effect on oxidative stress and survival under hypergravity in rodent model |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 22.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: This work provides characterization of withanolides and bacoside A proniosomes, and evaluating their potency in rat model for combating oxidative stress-induced blood-brain barrier (BBB) damage and their survival under hypergravity | ||
| 520 | |a SIGNIFICANCE: The delivery system was aimed for sustained drug release in plasma and brain, which could improve their efficiency and provide a therapeutic approach to combat oxidative damage and restore BBB integrity | ||
| 520 | |a METHODS: Proniosomes were prepared using withanolides extracted from the roots of W. somnifera and bacoside A derived from the leaf extract of B. monnieri by thin film hydration technique. In vitro release of withanolides and bacoside A from the proniosomes was studied. In vivo experiments were conducted in Wistar Albino rat model to evaluate the efficacy of drug-loaded proniosomes in improving the antioxidant activity in plasma and brain, restoring BBB integrity and combating hypergravity conditions | ||
| 520 | |a RESULTS: The withanolides and bacoside A-loaded proniosomes showed slow and sustained release of just 62.0 ± 2.87 and 62.9 ± 3.41%, respectively, in 9 h period against the release of 98-99% for the extracts that served as control. Trials conducted in vivo revealed a significant (p < .05) increase in the activity of antioxidant enzymes in both plasma and brain. Also, minimal extravasation of Evans blue dye into the brain (15 ± 0.03 and 16 ± 0.03 ng/g in treated groups against 110 ± 0.01 ng/g in control) of the rats fed with drug-loaded proniosomes was indicative of minimal damage to BBB. Rats fed with drug-loaded proniosomes survived to the extent of 75-83.3% against simulated hypergravity as compared to the control group in which only 50% survived | ||
| 520 | |a CONCLUSION: Proniosomes provided sustained release of drugs, which helped to protect BBB integrity, thereby combating hypergravity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BBB integrity | |
| 650 | 4 | |a Bacoside A | |
| 650 | 4 | |a hypergravity | |
| 650 | 4 | |a lipid peroxidation | |
| 650 | 4 | |a proniosomes | |
| 650 | 4 | |a withanolides | |
| 650 | 7 | |a bacoside A |2 NLM | |
| 650 | 7 | |a Withanolides |2 NLM | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 700 | 1 | |a David, Corbon Godfrey |e verfasserin |4 aut | |
| 700 | 1 | |a Pushpadass, Heartwin A |e verfasserin |4 aut | |
| 700 | 1 | |a Emerald Franklin, Magdaline Eljeeva |e verfasserin |4 aut | |
| 700 | 1 | |a Awachat, Vaibhav Bhagwan |e verfasserin |4 aut | |
| 700 | 1 | |a Kadakol, Veeranna R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug development and industrial pharmacy |d 1994 |g 49(2023), 12 vom: 30. Dez., Seite 748-758 |w (DE-627)NLM077783093 |x 1520-5762 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2023 |g number:12 |g day:30 |g month:12 |g pages:748-758 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03639045.2023.2286702 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2023 |e 12 |b 30 |c 12 |h 748-758 | ||